Company Profile For Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures and sells products in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through owned or leased facilities in the United States, Puerto Rico and 25 other countries. Eli Lilly and Company’s products are sold in approximately 135 countries. The Company also conducts research to find products to treat diseases in animals and to increase the efficiency of animal food production. Its principal products include Neurosciences products, Endocrinology products, Oncology products, Cardiovascular products, Animal health products and Other pharmaceuticals. On August 20, 2008, the Company acquired SGX Pharmaceuticals, Inc. (SGX). On November 24, 2008, the Company acquired ImClone Systems Inc. (ImClone), a biopharmaceutical company focused on advancing oncology care.

BRIEF: For the nine months ended 30 September 2009, Eli Lilly & Co.'s revenues rose 5% to $15.9B. Net income totaled $3.41B, up from $1.56B. Revenues reflect higher product sales and an increase in collaboration & other revenue. Net income also reflects lower cost of sales, the absence of acquired in-process research & development costs, lower asset impairment, restructuring & special charges and higher gross profit margin.